All Comers No More? US FDA AdComm Supports PD-L1 Threshold In Esophageal, Gastric Cancer

 
• By Bridget Silverman
  
cancer cells
ODAC members considered PD-1 risk-benefit questions in two types of cancer. • Source: Shutterstock
Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

SpotifyApple PodcastsWebsite

More from US FDA Performance Tracker

More from US Advisory Committees